Nuvalent Announced Cancer Discovery Publication Highlighting Design, Preclinical Activity, and Early Clinical Data of ALK-Selective Inhibitor NVL-655

Author: Benzinga Newsdesk | September 13, 2024 09:56am

- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-655 and details Nuvalent's approach to rationally targeting ALK. NVL-655 is currently being studied in the ongoing ALKOVE-1 Phase 1/2 clinical trial for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors.

Posted In: NUVL